Antioxidant compositions and their use in nucleic acid detection
Patent Information
- Application Number
- CN202280094851.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2022-09-09
- Publication Date
- 2024-12-06
AI Technical Summary
In the existing nucleic acid detection methods, laser irradiation and reactive oxygen groups cause nucleic acid damage, reducing the intensity and accuracy of detection signals. High-concentration nucleic acid protective agents are prone to salting out during low-temperature preservation and long-term storage, which increases the product cost. cost.
Combinations such as notoginseng saponin R1, glycyrrhizic acid or its derivatives, adenosine 5'-monophosphate or its salts, and carnosine are used as antioxidants. Through the joint action of multiple antioxidants, the nucleic acid is protected, light-induced damage is reduced, and the Effectively prevents oxidation and discoloration at low concentrations.
It effectively protects nucleic acids at low concentrations, improves sequencing quality and accuracy, and reduces error rates. It is especially suitable for short-read single-end sequencing, reduces second-strand signal rebound problems, and improves Q30 value and signal rebound value during paired-end sequencing.
Smart Images

Figure 00000032_0000 
Figure 00000032_0001
Abstract
Description
Antioxidant composition and its use in nucleic acid detection Technical Field
[0001] The present invention relates to the field of nucleic acid detection, and relates to an antioxidant composition, a reagent comprising the composition, a kit comprising the composition or reagent, use of the composition or reagent as a nucleic acid protective agent in nucleic acid detection, and a nucleic acid detection method. Background Art
[0002] Numerous nucleic acid detection methods (such as DNA sequencing, sequencing by synthesis, and sequencing by ligation) require excitation of fluorescent groups on the nucleic acid to be detected (or its complementary site) through light irradiation, such as laser irradiation. Information about the nucleic acid to be detected is then obtained through optical systems and base recognition software. The continuous, intense irradiation from the excitation light source and the presence of reactive oxygen groups in the solution can affect the nucleic acid, causing damage or degradation. This can lead to a loss of fluorescence signal intensity, which can reduce the number of detection cycles or decrease detection accuracy.
[0003] The buffer solution used in the base recognition process is called a scanning reagent or a photographing reagent. Laser damage to the template nucleotide can be prevented by adding a nucleic acid protective agent to the scanning reagent. The commercialized L-ascorbate combination formula can be used as an effective antioxidant and anti-photodamage nucleic acid protective agent for nucleic acid sequencing, and can support long read lengths, double-end sequencing, and has a low error rate. However, during long-term storage, L-ascorbate will change color after being oxidized, thereby affecting the scanning quality and, in turn, the sequencing quality of the polynucleotide. In addition, in the prior art, the concentration of the nucleic acid protective agent component in some scanning reagents is relatively high. The use of high-concentration nucleic acid protective agents makes it easy for the scanning reagent to precipitate when stored at low temperatures or during long-term sequencing. In addition, the use of high-concentration nucleic acid protective agents will increase product costs.
[0004] Summary of the Invention
[0005] Notoginsenoside R1 can be used as a nucleic acid protectant, protecting template nucleotides even at very low working concentrations. Furthermore, notoginsenoside R1 has no absorption in the UV-visible region, preventing interference with base recognition signals. Even if oxidized during long-term storage, it will not discolor.
[0006] In actual applications, the inventors found that Panax notoginseng saponin R1 is more suitable for short-read single-end sequencing as a nucleic acid protectant, and the sequencing error rate is low. However, when the number of sequencing cycles is large (especially double-end sequencing), the signal recovery and quality of the second chain are poor, so the accuracy and sequencing quality need to be improved.
[0007] To address the above issues, the present application provides an antioxidant composition comprising: notoginsenoside R1 or other saponin compounds, glycyrrhizic acid or its derivatives, and adenosine 5'-monophosphate or its salts, or carnosine; optionally, the composition further comprises other antioxidants. The antioxidant composition achieves the effect of better protecting nucleic acids and reducing light-induced damage through the combined action of multiple antioxidants.
[0008] Antioxidant composition
[0009] In one aspect, the present application provides a composition comprising:
[0010] (1) Saponin compounds, selected from one or more of notoginsenoside R1, ginsenoside Rg1, ginsenoside Rd, ginsenoside Rb2, ginsenoside Rb3, ginsenoside Rc, ginsenoside Rf, and ginsenoside Re;
[0011] (2) glycyrrhizic acid, a salt of glycyrrhizic acid, or a hydrate of a salt of glycyrrhizic acid; and
[0012] (3) adenosine 5'-monophosphate or its salts, or carnosine;
[0013] Optionally, the composition further comprises other antioxidants.
[0014] In this application, the structural formula of each saponin compound is as follows:
[0015]
[0016]
[0017] In some embodiments, the saponin compound is notoginsenoside R1.
[0018] Glycyrrhizic acid, also known as glycyrrhizin, is a triterpenoid compound. Its English name is Glycyrrhizic Acid, CAS number is 1405-86-3, and its molecular formula is C 42 H 62 O 16 , molecular weight is 822.93, chemical structure is as follows:
[0019]
[0020] Glycyrrhizic acid is easily soluble in hot water and ethanol, but has a lower solubility in cold water. It can be used in the form of salt or salt hydrate to increase its water solubility.
[0021] In the present application, the salt of glycyrrhizic acid refers to a salt formed by one, two or three carboxyl groups in glycyrrhizic acid and an appropriate inorganic or organic cation (base), including but not limited to: alkali metal salts, such as sodium salts, potassium salts, lithium salts, etc.; alkaline earth metal salts, such as calcium salts, magnesium salts, etc.; other metal salts, such as aluminum salts, iron salts, zinc salts, copper salts, nickel salts, cobalt salts, etc.; inorganic base salts, such as ammonium salts; organic base salts, such as tert-octylamine salts, dibenzylamine salts, morpholine salts, glucosamine salts, phenylglycine alkyl ester salts, ethylenediamine salts, N-methylglucosamine salts, guanidine salts, diethylamine salts, triethylamine salts, dicyclohexylamine salts, N,N'-dibenzylethylenediamine salts, chloroprocaine salts, procaine salts, diethanolamine salts, N-benzyl-phenethylamine salts, piperazine salts, tetramethylamine salts, tris(hydroxymethyl)aminomethane salts.
[0022] In some embodiments, the salt of glycyrrhizic acid is selected from an alkali metal salt or an ammonium salt, such as a monopotassium salt, a monosodium salt, a monoammonium salt, a dipotassium salt, a disodium salt, a diammonium salt, a tripotassium salt, a trisodium salt, or a triammonium salt.
[0023] In the present application, the hydrate of glycyrrhizic acid or the hydrate of a salt of glycyrrhizic acid refers to a substance formed by the association of glycyrrhizic acid or a salt of glycyrrhizic acid with one or more water molecules. The salt of glycyrrhizic acid can be any of the salts mentioned above.
[0024] In some embodiments, the hydrate of the salt of glycyrrhizic acid is selected from a hydrate of an alkali metal salt or an ammonium salt of glycyrrhizic acid, such as a hydrate of a sodium salt or a potassium salt.
[0025] In some embodiments, the salt of glycyrrhizic acid or the hydrate of the salt of glycyrrhizic acid is selected from:
[0026] Glycyrrhizic acid monoammonium salt, an exemplary structure of which is as follows:
[0027]
[0028] Trisodium glycyrrhizinate hydrate, an exemplary structure of which is as follows:
[0029]
[0030] Glycyrrhizic acid monopotassium salt, an exemplary structure of which is as follows:
[0031]
[0032] Diammonium glycyrrhizate, an exemplary structure of which is as follows:
[0033]
[0034] Dipotassium glycyrrhizate hydrate, an exemplary structure of which is as follows:
[0035]
[0036] Adenosine 5'-monophosphate has a CAS number of 61-19-8 and a molecular formula of C 10 H 14 N5O7P, molecular weight is 347.201, chemical structure is as follows:
[0037]
[0038] The salt of 5'-adenosine monophosphate is a salt formed by the phosphate group in 5'-adenosine monophosphate and one or two appropriate inorganic or organic cations (bases), or a salt formed by the amino group in 5'-adenosine monophosphate and one or two appropriate inorganic or organic anions (acids).
[0039] The salts formed by the phosphate group and one or two appropriate inorganic or organic cations (bases) include but are not limited to: alkali metal salts, such as sodium salts, potassium salts, lithium salts, etc.; alkaline earth metal salts, such as calcium salts, magnesium salts, etc.; other metal salts, such as aluminum salts, iron salts, zinc salts, copper salts, nickel salts, cobalt salts, etc.; inorganic base salts, such as ammonium salts; organic base salts, such as tert-octylamine salts, dibenzylamine salts, morpholine salts, glucosamine salts, phenylglycine alkyl ester salts, ethylenediamine salts, N-methylglucosamine salts, guanidine salts, diethylamine salts, triethylamine salts, dicyclohexylamine salts, N,N'-dibenzylethylenediamine salts, chloroprocaine salts, procaine salts, diethanolamine salts, N-benzyl-phenethylamine salts, piperazine salts, tetramethylamine salts, and tris(hydroxymethyl)aminomethane salts.
[0040] The salts formed by the amino group and one or two appropriate inorganic or organic anions (acids) include, but are not limited to: hydrohalides, such as hydrofluorides, hydrochlorides, hydrobromides, hydroiodides, etc.; inorganic acid salts, such as nitrates, perchlorates, sulfates, phosphates, etc.; lower alkanesulfonates, such as methanesulfonates, trifluoromethanesulfonates, ethanesulfonates, etc.; arylsulfonates, such as benzenesulfonates, p-toluenesulfonates, etc.; organic acid salts, such as acetates, malates, fumarates, succinates, citrates, tartrates, oxalates, maleates, etc.; amino acid salts, such as glycine, trimethylglycine, arginine, ornithine, glutamate, aspartate, etc.
[0041] In some embodiments, the salt of adenosine 5'-monophosphate is selected from an alkali metal salt, such as a sodium salt.
[0042] In some embodiments, the salt of adenosine 5'-monophosphate is adenosine 5'-monophosphate monosodium, and has the following chemical formula:
[0043]
[0044] Carnosine (L-Carnosine), scientifically known as β-alanyl-L-histidine, is a dipeptide composed of two amino acids, β-alanine and L-histidine. Its CAS number is 305-84-0 and its molecular formula is C9H 14 N4O3, molecular weight is 226.24, chemical structure is as follows:
[0045]
[0046] In some embodiments, the other antioxidant may be dithiothreitol (DTT) or Trolox (water-soluble vitamin E).
[0047] In some embodiments, in the composition, the molar ratio of the saponin compound to (glycyrrhizic acid, a salt of glycyrrhizic acid, or a hydrate of a salt of glycyrrhizic acid) is 4:1 to 1:10 (e.g., 4:1 to 3:1 (e.g., 1.67:0.5), 3:1 to 2:1, 2:1 to 1:1 (e.g., 1.67:1.5), 1:1 to 1:2 (e.g., 1.67:2.5), 1:2 to 1:3, 1:3 to 1:4, 1:4 to 1:5, 1:5 to 1:6, 1:6 to 1:7, 1:7 to 1:8, 1:8 to 1:9, or 1:9 to 1:10.
[0048] In some embodiments, in the composition, the molar ratio of the saponin compound to adenosine 5'-monophosphate or its salt to carnosine is 1:1 to 1:100 (e.g., 1:1 to 1:5 (e.g., 1.67:7.5), 1:5 to 1:10, 1:10 to 1:20, 1:20 to 1:30, 1:30 to 1:40, 1:40 to 1:50, 1:50 to 1:60, 1:60 to 1:70, 1:70 to 1:80, 1:80 to 1:90, or 1:90 to 1:100).
[0049] In some embodiments, in the composition, the molar ratio of saponin compounds to other antioxidants (such as DTT, Trolox, etc.) is 1:1 to 1:50 (e.g., 1:1 to 1:5 (e.g., 1.67:8), 1:5 to 1:10, 1:10 to 1:20 (e.g., 1.67:20), 1:20 to 1:30, 1:30 to 1:40, 1:40 to 1:50).
[0050] In some embodiments, in the composition, the molar ratio of (glycyrrhizic acid, a salt of glycyrrhizic acid, or a hydrate of a salt of glycyrrhizic acid): (adenosine 5'-monophosphate or a salt thereof or carnosine) is 1:1 to 1:15 (e.g., 1:1 to 1:3, 1:3 to 1:5, 1:5 to 1:10, or 1:10 to 1:15).
[0051] The ratio of each component in the composition of the present invention can be adjusted as needed (for example, the ratio in the above embodiment can be adopted) to obtain appropriate antioxidant properties to avoid excessive antioxidant properties that may damage dNTPs or DNBs and reduce sequencing quality.
[0052] Reagents, kits and their uses
[0053] In one aspect, the present application provides a reagent comprising the composition of the present invention and a buffer solution (eg, Tris buffer solution).
[0054] In the present invention, the Tris buffer solution refers to a buffer solution using tris (hydroxymethyl)aminomethane (Tris) as a buffer system.
[0055] Tris is widely used in the preparation of buffer solutions in biochemistry and molecular biology. Tris is a weak base, and its aqueous solution has a pH of approximately 10.5. By adding hydrochloric acid to adjust the pH to the desired value, a buffer solution of that pH is obtained. Buffer solutions can also be prepared using Tris and its hydrochloride (Tris-HCl).
[0056] Therefore, in some embodiments, the reagents include: water, a composition of the present invention, Tris Base, Tris-HCl, and optionally further include ethylenediaminetetraacetic acid and / or a solubilizer.
[0057] In some embodiments, the pH of the reagent is 6.0-9.0 (eg, 6.0-7.0, 7.0-8.0, or 8.0-9.0).
[0058] In some embodiments, the concentration of glycyrrhizic acid, a salt of glycyrrhizic acid, or a hydrate of a salt of glycyrrhizic acid is 0.1-10 mM, for example, 0.1-0.5 mM, 0.5-1 mM, 1-1.5 mM, 1.5-2.5 mM, 2.5-3 mM, 3-5 mM, 5-7 mM, or 7-10 mM.
[0059] In some embodiments, the concentration of the saponin compound is 0.1-5 mM, for example, 0.1-0.5 mM, 0.5-1 mM, 1-1.5 mM, 1.5-2.0 mM (e.g., 1.67 mM), 2.0-2.5 mM, 2.5-3 mM, 3-4 mM, or 4-5 mM. The solubility of the saponin compound in the reagent is limited, and an excess amount may be difficult to completely dissolve or even insoluble. Selecting the above concentration range allows the saponin compound to completely dissolve in the reagent.
[0060] In some embodiments, the concentration of adenosine 5'-monophosphate or a salt thereof or carnosine is 0.1-200 mM, for example, 0.1-0.5 mM, 0.5-1 mM, 1-1.5 mM, 1.5-2.5 mM, 2.5-3 mM, 3-5 mM, 5-7.5 mM, 7.5-10 mM, 10-30 mM, 30-50 mM, 50-75 mM, 75-100 mM, 100-120 mM, 120-150 mM, 150-180 mM or 180-200 mM.
[0061] In some embodiments, the concentration of the other antioxidant is 0.1-50 mM, such as 0.1-0.5 mM, 0.5-1 mM, 1-1.5 mM, 1.5-2.5 mM, 2.5-3 mM, 3-5 mM, 5-7.5 mM, 7.5-10 mM, 10-30 mM or 30-50 mM.
[0062] In some embodiments, the reagent is a scanning reagent.
[0063] In some embodiments, the scanning reagent comprises 1-2 M Tris buffer, 1-2 mM notoginsenoside R1, 0.5-2.5 mM glycyrrhizic acid, a salt of glycyrrhizic acid, or a hydrate of a salt of glycyrrhizic acid, 7-8 mM adenosine 5'-monophosphate or a salt thereof or carnosine, 8-9 mM Trolox, 9-10 mM ethylenediaminetetraacetic acid, and 10-20 mM DTT.
[0064] In certain embodiments, the reagent further comprises sodium chloride and / or a DNA stabilizer (e.g., Tween-20). The role of sodium chloride is to provide a salt solution background to protect the primers during detection.
[0065] In another aspect, the present application provides use of the composition or reagent of the present application as a nucleic acid protective agent in nucleic acid detection.
[0066] In certain embodiments, the nucleic acid protectant is used to protect nucleic acids to reduce or avoid photodamage (photoinduced damage) or oxidative damage.
[0067] In certain embodiments, the nucleic acid detection involves detecting a fluorescent signal. In certain embodiments, the fluorescent signal can be generated by an illumination reaction or a non-illumination reaction (e.g., a bioluminescent reaction). In certain embodiments, the bioluminescent reaction refers to a reaction in which luciferase catalyzes its substrate to produce a fluorescent signal.
[0068] In certain embodiments, the nucleic acid detection involves a light-induced reaction or a non-light-induced reaction (eg, a bioluminescent reaction).
[0069] As used herein, the term "photoreaction" refers to a reaction that is exposed to an optical energy source. Typically, in such reactions, the optical energy source (light) is provided to observe the production and / or consumption of reactants or products, which exhibit specific optical characteristics indicative of their presence, such as changes in the absorption and / or emission spectra (intensity, wavelength, etc.) of the reaction mixture or its components.
[0070] As used herein, the term "non-illuminated reaction" refers to a reaction that can be detected without the aid of an optical energy source. In non-illuminated reactions, the production and / or consumption of reactants or products can be detected by generating an optical signal, such as bioluminescence, or by altering an electrical signal.
[0071] In certain embodiments, the illumination reaction includes a light signal triggered by base extension or a light signal triggered by probe hybridization, and the base extension can cause the generation of an optical signal (eg, a fluorescent signal).
[0072] In certain embodiments, the light signal in the illumination reaction of the present invention is preferably fluorescence.
[0073] In certain embodiments, the nucleic acid detection is nucleic acid sequence determination (sequencing) or other detection, such as high-throughput sequencing, such as sequencing by synthesis (SBS sequencing), ligation sequencing, hybridization sequencing, nanopore sequencing, or combined probe-anchor ligation (cPAL) sequencing.
[0074] In certain embodiments, the nucleic acid detection is quantitative PCR.
[0075] In another aspect, the present application provides a kit comprising the composition or reagent of the present invention.
[0076] In certain embodiments, the kit of the present invention may further comprise one or more other reagents required for nucleic acid detection, for example, primers, polymerase, buffer solution, washing solution, or any combination thereof.
[0077] In certain embodiments, the kits of the present invention are used for nucleic acid sequence determination.
[0078] In certain embodiments, the kit of the present invention may further comprise: a reagent for fixing the nucleic acid molecule to be sequenced to a support (e.g., by covalent or non-covalent attachment); a primer for initiating nucleotide polymerization; a polymerase for carrying out nucleotide polymerization; one or more buffer solutions; one or more washing solutions; or any combination thereof.
[0079] In certain embodiments, the test kit of the present invention may also include reagents and / or devices for extracting nucleic acid molecules from a sample. Methods for extracting nucleic acid molecules from a sample are well known in the art. Therefore, various reagents and / or devices for extracting nucleic acid molecules may be configured as needed in the test kit of the present invention, such as reagents for crushing cells, reagents for precipitating DNA, reagents for washing DNA, reagents for dissolving DNA, reagents for precipitating RNA, reagents for washing RNA, reagents for dissolving RNA, reagents for removing protein, reagents for removing DNA (for example, when the target nucleic acid molecule is RNA), reagents for removing RNA (for example, when the target nucleic acid molecule is DNA), and any combination thereof.
[0080] In certain embodiments, test kit of the present invention also comprises, and is used for the reagent of pre-treatment nucleic acid molecule.In test kit of the present invention, the reagent for pre-treatment nucleic acid molecule is not subject to additional restriction, and can be selected according to actual needs.The described reagent for pre-treatment nucleic acid molecule comprises for example, and is used for the reagent (for example DNA enzyme I) of nucleic acid molecule fragmentation, and is used for the reagent (for example DNA polymerase, for example T4DNA polymerase, Pfu DNA polymerase, Klenow DNA polymerase) of polishing nucleic acid molecule end, joint molecule, label molecule, and is used for the reagent (for example ligase, for example T4DNA ligase) that joint molecule is connected with target nucleic acid molecule, and is used for the reagent (for example, losing 3'-5' exonuclease activity but showing 5'-3' exonuclease activity) of repairing nucleic acid end, and is used for the reagent (for example, DNA polymerase, primer, dNTP) of amplifying nucleic acid molecule, and is used for the reagent (for example chromatography column) of separation and purification nucleic acid molecule, and its any combination.
[0081] In certain embodiments, the kit of the present invention further comprises a support for fixing the nucleic acid molecules to be sequenced. Typically, the support for fixing the nucleic acid molecules to be sequenced is in a solid phase for ease of operation. Therefore, in this disclosure, "support" is sometimes also referred to as "solid support" or "solid phase support". However, it should be understood that the "support" mentioned herein is not limited to solid, and it can also be a semi-solid (e.g., gel).
[0082] As used herein, the terms "loaded," "fixed," and "attached" when used in reference to nucleic acids, mean attached directly or indirectly to a solid support via covalent or non-covalent bonds. In certain embodiments of the present disclosure, the methods of the present invention include immobilizing nucleic acids on a solid support via covalent attachment. Generally, however, it is only required that the nucleic acids remain fixed or attached to the solid support under conditions where the solid support is desired to be used (e.g., in applications where nucleic acid amplification and / or sequencing is required). In certain embodiments, immobilizing nucleic acids on a solid support can include immobilizing an oligonucleotide to be used as a capture primer or an amplification primer on a solid support such that the 3' end is available for enzymatic extension and at least a portion of the primer sequence is capable of hybridizing to a complementary nucleic acid sequence; the nucleic acid to be immobilized is then hybridized to the oligonucleotide, in which case the immobilized oligonucleotide or polynucleotide can be in a 3'-5' direction. In certain embodiments, immobilizing nucleic acids on a solid support can include binding a nucleic acid binding protein to the solid support by amino modification, and capturing nucleic acid molecules by the nucleic acid binding protein. Alternatively, loading can occur by other means besides base pair hybridization, such as covalent attachment as described above. Non-limiting examples of nucleic acid attachment to a solid support include nucleic acid hybridization, biotin-streptavidin binding, sulfhydryl binding, photoactivated binding, covalent binding, antibody-antigen, physical confinement via a hydrogel or other porous polymer, and the like. Various exemplary methods for immobilizing nucleic acids on solid supports can be found in, for example, G. Steinberg-Tatman et al., Bioconjugate Chemistry 2006, 17, 841-848; Xu X. et al. Journal of the American Chemical Society 128 (2006) 9286-9287; U.S. patent applications US 5639603, US 5641658, US2010248991; international patent applications WO 2001062982, WO 2001012862, WO 2007111937, WO0006770, all of which are incorporated herein by reference in their entirety for all purposes, in particular for all teachings relating to the preparation of solid supports having nucleic acids immobilized thereon.
[0083] In the present invention, the support can be made of various suitable materials. Such materials include, for example, inorganic substances, natural polymers, synthetic polymers, and any combination thereof. Specific examples include, but are not limited to, cellulose, cellulose derivatives (e.g., nitrocellulose), acrylic resins, glass, silica gel, silicon dioxide, polystyrene, gelatin, polyvinyl pyrrolidone, copolymers of vinyl and acrylamide, cross-linked polystyrenes such as divinylbenzene (see, for example, Merrifield Biochemistry 1964, 3, 1385-1390), polyacrylamide, latex, dextran, rubber, silicon, plastics, natural sponges, metal plastics, cross-linked dextran (e.g., Sephadex TM ), agarose gel (Sepharose TM ), and other supports known to those skilled in the art.
[0084] In certain preferred embodiments, the support used to immobilize the nucleic acid molecules to be sequenced can be a solid support comprising an inert substrate or matrix (e.g., a glass slide, polymer beads, etc.) that has been functionalized, for example, by applying an intermediate material containing reactive groups that allow for covalent attachment of biomolecules such as polynucleotides. Examples of such supports include, but are not limited to, polyacrylamide hydrogels supported on an inert substrate such as glass, particularly the polyacrylamide hydrogels described in WO 2005 / 065814 and US 2008 / 0280773, the contents of which are incorporated herein by reference in their entirety. In such embodiments, the biomolecules (e.g., polynucleotides) can be directly covalently attached to the intermediate material (e.g., hydrogel), while the intermediate material itself can be non-covalently attached to the substrate or matrix (e.g., a glass substrate). In certain preferred embodiments, the support is a glass or silicon wafer whose surface is modified with a layer of avidin, amino, acrylamide silane, or aldehyde chemical groups.
[0085] In the present invention, the support or solid support is not limited to its size, shape and configuration. In some embodiments, the support or solid support is a planar structure, such as a slide, chip, microchip and / or array. The surface of such a support can be in the form of a planar layer.
[0086] In certain preferred embodiments, the support for immobilizing the nucleic acid molecules to be sequenced is an array of beads or wells (also referred to as a chip). The array can be prepared using any of the materials outlined herein for preparing solid supports, and preferably, the surface of the beads or wells on the array is functionalized to facilitate the immobilization of nucleic acid molecules. The number of beads or wells on the array is not limited. For example, each array may contain 10-10 2 , 10 2-10 3 , 10 3 -10 4 , 10 4 -10 5 , 10 5 -10 6 , 10 6 -10 7 , 10 7 -10 8 , 10 8 -10 9 , 10 10 -10 11 , 10 11 -10 12 In certain exemplary embodiments, the surface of each bead or hole can be fixed with one or more nucleic acid molecules. Accordingly, each array can be fixed with 10-10 2 , 10 2 -10 3 , 10 3 -10 4 , 10 4 -10 5 , 10 5 -10 6 , 10 6 -10 7 , 10 7 -10 8 , 10 8 -10 9 , 10 10 -10 11 , 10 11 -10 12 or more nucleic acid molecules. Therefore, such arrays can be particularly advantageously used for high-throughput sequencing of nucleic acid molecules.
[0087] In certain preferred embodiments, the kit of the present invention further comprises a reagent for fixing the nucleic acid molecule to be sequenced to the support (e.g., by covalent or non-covalent attachment). Such reagents include, for example, reagents for activating or modifying nucleic acid molecules (e.g., their 5' ends), such as phosphoric acid, thiol, amine, carboxylic acid, or aldehyde; reagents for activating or modifying the surface of the support, such as amino-alkoxysilanes (e.g., aminopropyltrimethoxysilane, aminopropyltriethoxysilane, 4-aminobutyltriethoxysilane, etc.); cross-linking agents, such as succinic anhydride, phenyl diisocyanate (Guo et al., 1994), maleic anhydride (Yang et al., 1998), 1-ethyl-3-(3-dimethoxysilane)-1-ol; methylaminopropyl)-carbodiimide hydrochloride (EDC), m-maleimidobenzoic acid-N-hydroxysuccinimide ester (MBS), N-succinimidyl[4-iodoacetyl]aminobenzoic acid (SIAB), 4-(N-maleimidomethyl)cyclohexane-1-carboxylic acid succinimide (SMCC), N-γ-maleimidobutyryloxy-succinimide ester (GMBS), 4-(p-maleimidophenyl)butyric acid succinimide (SMPB); and any combination thereof.
[0088] In certain preferred embodiments, the kit of the present invention also includes a primer for initiating nucleotide polymerization. In the present invention, the primer is not subject to additional restrictions, as long as it can specifically anneal to a region of the target nucleic acid molecule. In some exemplary embodiments, the length of the primer can be 5-50bp, such as 5-10, 10-15, 15-20, 20-25, 25-30, 30-35, 35-40, 40-45, 45-50bp. In some exemplary embodiments, the primer can include naturally occurring or non-naturally occurring nucleotides. In some exemplary embodiments, the primer includes naturally occurring nucleotides or is composed of naturally occurring nucleotides. In some exemplary embodiments, the primer includes modified nucleotides, such as locked nucleic acid (LNA). In certain preferred embodiments, the primer includes a universal primer sequence.
[0089] In some preferred embodiments, test kit of the present invention also comprises the polymerase for carrying out nucleotide polymerization reaction.In the present invention, various suitable polymerases can be used to carry out polyreaction.In some exemplary embodiments, described polymerase can be the new DNA chain (such as DNA polymerase) synthesized with DNA as a template.In some exemplary embodiments, described polymerase can be the new DNA chain (such as reverse transcriptase) synthesized with RNA as a template.In some exemplary embodiments, described polymerase can be the new RNA chain (such as RNA polymerase) synthesized with DNA or RNA as a template.Therefore, in some preferred embodiments, described polymerase is selected from DNA polymerase, RNA polymerase, and reverse transcriptase.
[0090] In certain preferred embodiments, the kit of the present invention further comprises one or more excision reagents. In certain embodiments, the excision reagent is selected from endonuclease IV and alkaline phosphatase.
[0091] In certain preferred embodiments, the kit of the present invention further comprises one or more buffer solutions. Such buffer solutions include, but are not limited to, buffer solutions for DNA enzyme I, buffer solutions for DNA polymerase, buffer solutions for ligase, buffer solutions for eluting nucleic acid molecules, buffer solutions for dissolving nucleic acid molecules, buffer solutions for carrying out nucleotide polymerization reactions (e.g., PCR), and buffer solutions for carrying out ligation reactions. The kit of the present invention may comprise any one or more of the above-mentioned buffer solutions.
[0092] In the present invention, "buffer" and "buffer solution" have the same meaning and can be used interchangeably.
[0093] In certain embodiments, the buffer solution for DNA polymerase comprises monovalent salt ions (e.g., sodium ions, chloride ions) and / or divalent salt ions (e.g., magnesium ions, sulfate ions, manganese ions). In certain embodiments, the concentration of the monovalent salt ions or divalent salt ions in the buffer solution is 10 μM-200 mM, e.g., 10 μM, 50 μM, 100 μM, 200 μM, 500 μM, 1 mM, 3 mM, 10 mM, 20 mM, 50 mM, 100 mM, 150 mM, or 200 mM.
[0094] In certain embodiments, the buffer solution for DNA polymerase comprises tris (hydroxymethylaminomethane) (Tris).In certain embodiments, the concentration of Tris in the buffer solution is 10mM-200mM, such as 10mM, 20mM, 50mM, 100mM, 150mM or 200mM.
[0095] In certain embodiments, the buffer solution for DNA polymerase comprises an organic solvent, such as DMSO or glycerol (glycerol). In certain embodiments, the mass content of the organic solvent in the buffer solution is 0.01%-10%, such as 0.01%, 0.02%, 0.05%, 1%, 2%, 5% or 10%.
[0096] In certain embodiments, the pH of the buffer solution for DNA polymerase is 7.0-9.0, e.g., 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9 or 9.0.
[0097] In certain embodiments, the buffer solution for DNA polymerase comprises: monovalent salt ions (e.g., sodium ions, chloride ions), divalent salt ions (e.g., magnesium ions, sulfate ions, manganese ions), Tris, and an organic solvent (e.g., DMSO or glycerol). In certain embodiments, the pH of the buffer solution phase is 8.8.
[0098] In certain preferred embodiments, the kit of the present invention further comprises one or more washing solutions. Examples of such washing solutions include, but are not limited to, phosphate buffer, citrate buffer, Tris-HCl buffer, acetate buffer, carbonate buffer, and the like. The kit of the present invention may comprise any one or more of the above-mentioned washing solutions.
[0099] In another aspect, the present application provides the use of the compositions, reagents or kits of the present invention for nucleic acid detection. In certain embodiments, the nucleic acid detection involves detecting a fluorescent signal. In certain embodiments, the fluorescent signal can be generated by an illumination reaction or a non-illumination reaction (e.g., a bioluminescent reaction). In certain embodiments, the bioluminescence refers to a reaction in which luciferase catalyzes its substrate to produce a fluorescent signal. In certain embodiments, the nucleic acid detection involves an illumination reaction or a non-illumination reaction (e.g., a bioluminescent reaction). In certain embodiments, the illumination reaction includes base extension, which can cause the generation of an optical signal (e.g., a fluorescent signal). In certain embodiments, the optical feature in the illumination reaction described in the present invention is preferably fluorescence. In certain embodiments, the nucleic acid detection can be used for nucleic acid sequence determination (sequencing) or other scenarios (e.g., quantitative PCR). In certain embodiments, the nucleic acid detection is nucleic acid sequence determination, such as high-throughput sequencing, such as SBS sequencing, ligation sequencing, hybridization sequencing, nanopore sequencing, or cPAL sequencing. In certain embodiments, the nucleic acid detection is quantitative PCR.
[0100] In another aspect, the present application provides a method for preparing the reagent of the present invention, comprising dissolving the components of the reagent in ultrapure water to form a transparent and uniform solution, and then filtering the solution to obtain the reagent of the present invention. Ultrasound can be used to assist the dissolution.
[0101] In another aspect, the present application provides a method for inhibiting nucleic acid degradation, comprising using a composition or reagent of the present invention as a nucleic acid protective agent. In some embodiments, the nucleic acid degradation is light-induced nucleic acid degradation or nucleic acid degradation caused by oxidation. In some embodiments, the method comprises: in the presence of the composition or reagent, performing an illumination reaction or a non-illumination reaction (e.g., a bioluminescent reaction) on a reaction mixture containing nucleic acid.
[0102] In another aspect, the present application provides a method for detecting a target nucleic acid molecule, comprising using a composition or reagent of the present invention as a nucleic acid protectant. In some embodiments, the method comprises: performing an illumination reaction or a non-illumination reaction (e.g., a bioluminescent reaction) on a reaction mixture comprising the target nucleic acid molecule in the presence of the composition or reagent.
[0103] In certain embodiments, the method includes: performing signal acquisition and detecting fluorescent signals on the reaction mixture; wherein the reaction mixture comprises reactants that can generate fluorescent signals (e.g., fluorescently labeled reactants), target nucleic acid molecules, and a buffer, and the buffer comprises a composition of the present invention.
[0104] In certain embodiments, the fluorescent signal is generated by a photoluminescence reaction or a bioluminescence reaction.
[0105] In certain embodiments, the method comprises: irradiating the reaction mixture with light, and detecting a fluorescent signal from the illumination reaction; wherein the reaction mixture comprises a fluorescently labeled reactant, a target nucleic acid molecule, and a buffer, and the buffer comprises the composition of the present invention.
[0106] In certain embodiments, the reaction mixture for performing a photoreaction comprises a composition or reagent of the invention.
[0107] In certain embodiments, the method is used for nucleic acid sequence determination. In certain embodiments, the sequencing is high-throughput sequencing. In certain embodiments, the sequencing is SBS sequencing, ligation sequencing, hybridization sequencing, nanopore sequencing, or cPAL sequencing.
[0108] In certain embodiments, the reactants that can generate a fluorescent signal include: labeled or unlabeled nucleotides (e.g., dNTPs), optionally further comprising other reagents that allow the reactants to generate a fluorescent signal. In certain embodiments, each reactant that can generate a fluorescent signal corresponds to a type of nucleotide, and each reactant can generate a signal that is distinguishable from each other to identify the incorporation of a specific nucleotide. For example, four reactants each containing adenine, guanine, cytosine, and thymine to be incorporated can generate different fluorescent signals, making them easy to distinguish from each other.
[0109] In certain embodiments, the nucleotides in the reactant capable of generating a fluorescent signal (eg, fluorescently labeled nucleotides) further carry a blocking group (eg, a 3' blocking group) to reversibly prevent further base extension.
[0110] In certain embodiments, the nucleotides (eg, fluorescently labeled nucleotides) in the reactants capable of generating a fluorescent signal are selected from nucleoside polyphosphates (or analogs thereof), such as dNTPs.
[0111] In certain embodiments, the reaction mixture further comprises an enzyme, such as a polymerase, a helicase, an exonuclease, or a ligase; preferably, the reaction mixture comprises a polymerase, such as a DNA polymerase.
[0112] In certain embodiments, the reaction mixture further comprises a primer.
[0113] In certain embodiments, the method comprises: incorporating a nucleotide (e.g., a fluorescently labeled nucleotide) from a reactant that generates a fluorescent signal into a complementary strand of a target nucleic acid molecule; in the presence of a composition or reagent of the present invention, providing conditions that allow the reactant to generate a fluorescent signal, detecting the fluorescent signal of the reaction mixture (e.g., irradiating the reaction mixture), and determining the identity of the incorporated nucleotide. In certain embodiments, determining the identity of the incorporated nucleotide comprises detecting (e.g., photographing) a fluorescent signal (e.g., a fluorescent label) associated with the incorporated nucleotide.
[0114] In certain embodiments, the method further comprises: removing a moiety (e.g., a fluorescent label) that is directly or indirectly attached to the incorporated nucleotide and that generates a fluorescent signal; and / or, washing to remove unincorporated nucleotides. In certain embodiments, the method further comprises: removing a blocking group from the incorporated nucleotide to allow further extension.
[0115] In certain embodiments, the methods comprise multiple incorporations and determining the identity of the base present in each incorporated nucleotide to determine the sequence of the target nucleic acid molecule.
[0116] In certain embodiments, the target nucleic acid molecule is present in a nucleic acid array. In certain embodiments, each site on the array can include multiple copies of a single target nucleic acid molecule. In certain embodiments, the nucleic acid array is fixed to a solid support, such as a chip.
[0117] In another aspect, the present application provides a method for detecting a nucleic acid sequence, comprising: incorporating one or more labeled modified nucleotides into a nucleic acid chain complementary to a nucleic acid template chain, and determining the type of the one or more incorporated nucleotides by detecting the label, wherein the step of determining the type of incorporated nucleotides is performed in a buffer comprising a composition of the present invention.
[0118] In certain embodiments, the label is a label that can generate a fluorescent signal. In certain embodiments, the fluorescent signal is generated by an illumination reaction or a bioluminescent reaction. In certain embodiments, the method is used for nucleic acid sequence determination (sequencing). In certain embodiments, the nucleotide with a label modification is: (1) a fluorescently labeled nucleotide (e.g., dNTP); or (2) a nucleotide with a label (e.g., dNTP), and the label can specifically bind to luciferase.
[0119] In certain embodiments, the step of determining the type of incorporated nucleotide comprises: providing conditions that allow the label to produce a fluorescent signal in the presence of a composition of the present invention, detecting the fluorescent signal in the buffer solution, and determining the identity of the incorporated nucleotide. Optionally, the method further comprises: removing a portion of the incorporated nucleotide that is directly or indirectly attached thereto and that produces a fluorescent signal; and / or, washing to remove unincorporated nucleotides. In certain embodiments, the method comprises multiple incorporations and determining the identity of the base present in each incorporated nucleotide to determine the sequence of the target nucleic acid molecule.
[0120] In certain embodiments, the buffer solution is a Tris buffer solution. In certain embodiments, the pH of the buffer solution is 6.0 to 9.0. In certain embodiments, in the buffer solution, the concentration of glycyrrhizic acid, a salt of glycyrrhizic acid, or a hydrate of a salt of glycyrrhizic acid is 0.1 to 10 mM. In certain embodiments, in the buffer solution, the concentration of adenosine 5'-monophosphate or a salt thereof or carnosine is 0.1 to 200 mM. In certain embodiments, in the buffer solution, the concentration of the other antioxidant is 0.1 to 50 mM. In certain embodiments, the buffer solution is a scanning reagent.
[0121] In certain embodiments, the method is used for nucleic acid sequence determination. In certain embodiments, the sequencing is high-throughput sequencing. In certain embodiments, the sequencing is SBS sequencing, ligation sequencing, hybridization sequencing, nanopore sequencing, or cPAL sequencing.
[0122] Light-induced sequencing
[0123] In certain embodiments, the fluorescent signal is generated by an illumination reaction. In such embodiments, the label is preferably a fluorescent label. In certain embodiments, the method comprises: irradiating the reaction mixture with light, and detecting a fluorescent signal from the illumination reaction; wherein the reaction mixture comprises reactants capable of generating a fluorescent signal, a target nucleic acid molecule, and a buffer, wherein the buffer comprises a composition of the present invention. In certain embodiments, the reaction mixture subjected to the illumination reaction comprises a composition or reagent of the present invention.
[0124] In certain embodiments, the reactants capable of generating a fluorescent signal include fluorescently labeled nucleotides (e.g., dNTPs). In certain embodiments, the fluorescent label can be linked to the nucleotide (e.g., its base) via a linker. The linker can be acid-labile, photolabile, or contain a disulfide bond.
[0125] In certain embodiments, the method comprises: incorporating fluorescently labeled nucleotides into the complementary strand of the target nucleic acid molecule; irradiating the reaction mixture in the presence of a composition or reagent of the present invention, and determining the identity of the incorporated nucleotides. In certain embodiments, determining the identity of the incorporated nucleotides comprises detecting (e.g., taking a photo of) the fluorescent label of the incorporated nucleotides. In certain embodiments, the method further comprises: removing the fluorescent label attached to the incorporated nucleotides; and / or, washing to remove unincorporated nucleotides. In certain embodiments, the method further comprises: removing blocking groups from the incorporated nucleotides to allow further extension.
[0126] In certain embodiments, the reactants that can generate fluorescent signals include: unlabeled nucleotides (e.g., dNTPs) and fluorescently labeled affinity reagents (e.g., antibodies), and the affinity reagents can specifically bind to the unlabeled nucleotides. Such embodiments may be referred to as Cool MPS sequencing, and detailed teachings thereof may refer to PCT International Application WO2018129214A1. In such embodiments, based on the SBS sequencing principle, the fluorescent group is not directly labeled on the incorporated nucleotides, but is labeled on an affinity reagent (e.g., an antibody, an aptamer, an Affimer, a Knottin, etc.), and the affinity reagent can specifically bind to the bases, sugars, cleavable blocking groups, or a combination of these components incorporated into the nucleotides, and therefore the type of incorporated nucleotides can be identified by the affinity reagent.
[0127] In certain embodiments, the method comprises: incorporating unlabeled nucleotides into the complementary strand of the target nucleic acid molecule; providing a fluorescently labeled affinity reagent and indirectly attaching the fluorescent label to the incorporated nucleotide through specific binding between the affinity reagent and the nucleotide; irradiating the reaction mixture in the presence of a composition or reagent of the present invention, and determining the identity of the incorporated nucleotide. In certain embodiments, the determination of the identity of the incorporated nucleotide comprises detecting (e.g., taking a photo of) the fluorescent label of the affinity reagent to which the incorporated nucleotide is attached. In certain embodiments, the method further comprises: removing the affinity reagent attached to the incorporated nucleotide; and / or, washing to remove unincorporated nucleotides. In certain embodiments, the method further comprises: removing the blocking group from the incorporated nucleotide to allow further extension.
[0128] Sequencing based on bioluminescence reactions
[0129] In certain embodiments, the fluorescent signal is generated by a bioluminescent reaction. The detection principle of bioluminescence includes that the nucleotide to be incorporated is not directly labeled with a fluorescent signal, but is labeled with an affinity substance such as biotin or digoxin. After the polymerization reaction, a pairing member of the above affinity substance with luciferase is added to bind the luciferase to the incorporated nucleotide, and then a reaction substrate is added to generate a light signal to identify the identity of the incorporated nucleotide. This process does not require excitation light irradiation. Detailed teachings on bioluminescent reactions can be found in, for example, PCT International Application WO2020227953A1.
[0130] In certain embodiments, the reactants capable of generating a fluorescent signal include: a nucleotide with a tag (eg, dNTP), a luciferase capable of specifically binding to the tag, and a substrate of the luciferase.
[0131] In certain embodiments, the tag carried by the nucleotide is a member of any molecular pair that can specifically bind to each other. Specific binding between the pairing members realizes the connection between the nucleotide and the luciferase. Exemplary pairing members include, but are not limited to: (a) haptens or antigenic compounds in combination with corresponding antibodies or their binding portions or fragments, such as digoxin-digoxin antibodies, N3G-N3G antibodies, FITC-FITC antibodies; (b) nucleic acid aptamers and proteins; (c) non-immune binding pairs (e.g., biotin-avidin, biotin-streptavidin, biotin-neutravidin); (d) hormone-hormone binding protein; (e) receptor-receptor agonist or antagonist; (f) lectin-carbohydrate; (g) enzyme-enzyme cofactor; (h) enzyme-enzyme inhibitor; and (i) complementary oligonucleotides or polynucleotides capable of forming nucleic acid duplexes.
[0132] In certain embodiments, the label carried by the nucleotide is a small molecule label selected from biotin, digoxigenin, N3G or FITC, and the luciferase carries a pairing member corresponding to the small molecule label. For example, in a specific embodiment, if the label carried by the nucleotide is biotin, the luciferase can be a luciferase labeled with streptavidin; if the label carried by the nucleotide is digoxigenin, the luciferase can be a luciferase labeled with a digoxigenin antibody. The sources of the luciferase include but are not limited to organisms such as firefly, gaussia, and Renilla. For example, the luciferase labeled with streptavidin can be SA-Gluc:Streptavidin-Gaussia princeps luciferase from Adivity. The luciferase labeled with a digoxigenin antibody can be digoxin antibody-Gluc or digoxin antibody-Nluc.
[0133] In certain embodiments, the method comprises: incorporating a tagged nucleotide into a complementary strand of a target nucleic acid molecule; providing a luciferase connected to a pairing member capable of specifically binding to the tag, and indirectly connecting the luciferase to the incorporated nucleotide through specific binding between the pairing members; providing a substrate for the luciferase in the presence of a composition or reagent of the present invention to generate a fluorescent signal, thereby determining the identity of the incorporated nucleotide. In certain embodiments, the method further comprises: removing the luciferase connected to the incorporated nucleotide; and / or, washing to remove unincorporated nucleotides. In certain embodiments, the method further comprises: removing a blocking group from the incorporated nucleotide to allow further extension.
[0134] In certain embodiments, the method can also be used for quantitative PCR. In certain embodiments, the reactant that can generate a fluorescent signal is a fluorescent probe. In certain embodiments, the reaction mixture further comprises an enzyme, such as a polymerase, a helicase, an exonuclease, or a ligase; preferably, the reaction mixture comprises a polymerase, such as a DNA polymerase. In certain embodiments, the reaction mixture further comprises a primer.
[0135] The following discussion will use synthesis sequencing as an example, which is not meant to be limiting. All uses and methods of using the reagents of the present invention in a nucleic acid detection step involving an illumination reaction are within the scope of the present invention.
[0136] In another aspect, the present application provides a method for nucleic acid sequencing, comprising using the composition, reagent, or kit of the present invention. In certain embodiments, the sequencing method of the present invention comprises synthesizing a growing polynucleotide complementary to a target single-stranded polynucleotide while performing scanning and photographing detection.
[0137] In certain embodiments, the method for determining the sequence of a target single-stranded polynucleotide comprises:
[0138] (a) providing a duplex, nucleotides, a polymerase, and an excision reagent; the duplex comprises a growing nucleic acid chain and a nucleic acid molecule to be sequenced;
[0139] (b) performing a reaction cycle comprising the following steps (i), (ii) and (iii):
[0140] Step (i): using a polymerase to incorporate nucleotides into the growing nucleic acid chain to form a nucleic acid intermediate comprising a blocking group and a detectable label;
[0141] Step (ii): detecting the detectable label on the nucleic acid intermediate in the presence of a composition or reagent of the present invention;
[0142] Step (iii): using a cleavage reagent to remove the blocking group on the nucleic acid intermediate.
[0143] In certain embodiments, the reaction cycle further comprises step (iv): removing the detectable label on the nucleic acid intermediate using a cleavage reagent.
[0144] In certain embodiments, the method comprises the steps of:
[0145] The first step is to load DNA nanoballs (DNBs) onto the prepared sequencing chip;
[0146] In the second step, the prepared dNTP molecule mixture solution is pumped into the chip and DNA polymerase is used to add dNTPs to the complementary strand of the DNA to be tested;
[0147] The third step is photo scanning. Since dNTPs are modified molecules with fluorescent groups, laser is used as the excitation wavelength for photography. Since laser can cause photodamage to DNA, a scanning reagent containing a nucleic acid protectant is added during this step to take photos.
[0148] In the fourth step, the base-end fluorescent group and the 3' blocker are removed and washed away by the removal reagent, leaving the 3'-OH group exposed for the next round of reaction.
[0149] The fifth step is to determine the base sequence of the nucleic acid molecule to be tested by analyzing the photographic results.
[0150] In the present invention, nucleic acids may include nucleotides or nucleotide analogs. Nucleotides generally contain a sugar, a nucleobase, and at least one phosphate group. Nucleotides include deoxyribonucleotides, modified deoxyribonucleotides, ribonucleotides, modified ribonucleotides, peptide nucleotides, modified peptide nucleotides, modified phosphate sugar backbone nucleotides, and mixtures thereof. Examples of nucleotides include, for example, adenosine monophosphate (AMP), adenosine diphosphate (ADP), adenosine triphosphate (ATP), thymidine monophosphate (TMP), thymidine diphosphate (TDP), thymidine triphosphate (TTP), cytidylic acid (CMP), cytidylic acid diphosphate (CDP), cytidylic acid triphosphate (CTP), guanosine monophosphate (GMP), guanosine diphosphate (GDP), guanosine triphosphate (GTP), uridine monophosphate (UMP), uridine diphosphate (UDP), uridine triphosphate (UTP), deoxyadenosine monophosphate (dAMP), Deoxyadenosine diphosphate (dADP), deoxyadenosine triphosphate (dATP), deoxythymidine monophosphate (dTMP), deoxythymidine diphosphate (dTDP), deoxythymidine triphosphate (dTTP), deoxycytidine diphosphate (dCDP), deoxycytidine triphosphate (dCTP), deoxyguanosine monophosphate (dGMP), deoxyguanosine diphosphate (dGDP), deoxyguanosine triphosphate (dGTP), deoxyuridine monophosphate (dUMP), deoxyuridine diphosphate (dUDP) and deoxyuridine triphosphate (dUTP). Nucleotide analogs comprising modified nucleobases can also be used in the methods described herein. Exemplary modified nucleobases that can be included in polynucleotides, whether having a natural backbone or an analogous structure, include, for example, inosine, xanthine, hypoxanthine, isocytosine, isoguanine, 2-aminopurine, 5-methylcytosine, 5-hydroxymethylcytosine, 2-aminoadenine, 6-methyladenine, 6-methylguanine, 2-propylguanine, 2-propyladenine, 2-thiouracil, 2-thiothymine, 2-thiocytosine, 15-halouracil, 15-halocytosine, 5-propynyluracil, 5-propynyl Cytosine, 6-azouracil, 6-azocytosine, 6-azothymidine, 5-uracil, 4-thiouracil, 8-haloadenine or guanine, 8-aminoadenine or guanine, 8-thioadenine or guanine, 8-sulfanyladenine or guanine, 8-hydroxyadenine or guanine, 5-halosubstituted uracil or cytosine, 7-methylguanine, 7-methyladenine, 8-azaguanine, 8-azaadenine, 7-deazaguanine, 7-deazaadenine, 3-deazaguanine, 3-deazaadenine, etc. As is known in the art, certain nucleotide analogs cannot be incorporated into polynucleotides, for example, nucleotide analogs such as adenosine 5'-phosphosulfate.
[0151] In the method of the present invention, the nucleic acid molecule to be sequenced is not limited by its length. In certain preferred embodiments, the length of the nucleic acid molecule to be sequenced can be at least 10bp, at least 20bp, at least 30bp, at least 40bp, at least 50bp, at least 100bp, at least 200bp, at least 300bp, at least 400bp, at least 500bp, at least 1000bp, or at least 2000bp. In certain preferred embodiments, the length of the nucleic acid molecule to be sequenced can be 10-20bp, 20-30bp, 30-40bp, 40-50bp, 50-100bp, 100-200bp, 200-300bp, 300-400bp, 400-500bp, 500-1000bp, 1000-2000bp, or more than 2000bp. In certain preferred embodiments, the nucleic acid molecule to be sequenced can have a length of 10-1000bp, to facilitate high-throughput sequencing.
[0152] In certain preferred embodiments, the nucleic acid molecules may be pretreated before being fixed to a support. Such pretreatments include, but are not limited to, fragmentation of the nucleic acid molecules, end-padding, addition of adapters, addition of tags, amplification of the nucleic acid molecules, separation and purification of the nucleic acid molecules, and any combination thereof.
[0153] The term "nanosphere" as used herein generally refers to a macromolecule or complex having a compact, (approximately) spherical shape, eg, with an inner diameter typically ranging between about 1 nm and about 1000 nm, preferably between about 50 nm and about 500 nm.
[0154] As used herein, the term "nucleic acid nanoball" is generally a concatemer comprising multiple copies of a target nucleic acid molecule. These nucleic acid copies are typically arranged one after another in a continuous linear chain of nucleotides, but the nucleic acid nanoballs of the present invention can also be made from any nucleic acid molecule using the methods described herein. This tandem repeat structure, together with the single-stranded nature of DNA, causes the nanoball to fold (folding) configuration. Generally speaking, the multiple copies of the target nucleic acid molecules in the nucleic acid nanoball each contain a linker sequence with a known sequence to facilitate amplification or sequencing thereof. The linker sequences of each target nucleic acid molecule are generally the same, but may also be different. Nucleic acid nanoballs generally include DNA nanoballs, also referred to herein as DNBs (DNA nanoballs).
[0155] Nucleic acid nanospheres can be produced using, for example, rolling circle replication (RCA). The RCA process has been used to prepare multiple continuous copies of the M13 genome (Blanco et al., (1989) J Biol Chem 264:8935-8940). In this method, nucleic acids are replicated through linear concatemerization. Those skilled in the art can find guidance on the conditions and reagents for selecting RCA reactions in many references, including U.S. Patents US5,426,180, US5,854,033, US6,143,495 and US5,871,921, for all purposes, particularly for all teachings related to the preparation of nucleic acid nanospheres using RCA or other methods, which are incorporated herein by reference in their entirety.
[0156] The nucleic acid nanospheres can be loaded onto the surface of a solid support as described herein. The nanospheres can be attached to the surface of the solid support by any suitable method, non-limiting examples of which include nucleic acid hybridization, biotin-streptavidin binding, sulfhydryl binding, photoactivated binding, covalent binding, antibody-antigen, physical confinement via a hydrogel or other porous polymer, or a combination thereof. In some cases, the nanospheres can be digested with a nuclease (e.g., a DNA nuclease) to generate smaller nanospheres or fragments from the nanospheres.
[0157] In certain embodiments, the solid support surface may have reactive functional groups that react with complementary functional groups on the polynucleotide molecules to form covalent bonds, for example, using the same techniques used to attach cDNA to microarrays, for example, see Smirnov et al. (2004), Genes, Chromosomes & Cancer, 40: 72-77 and Beaucage (2001), Current Medicinal Chemistry, 8: 1213-1244, both of which are incorporated herein by reference. DNB can also effectively attach to hydrophobic surfaces, such as clean glass surfaces with low concentrations of various reactive functional groups (e.g., -OH groups). Attachment via covalent bonds formed between polynucleotide molecules and reactive functional groups on the surface is also referred to herein as "chemical attachment."
[0158] In other embodiments, the polynucleotide molecules can be adsorbed onto a surface. In this embodiment, the polynucleotide is immobilized by non-specific interactions with the surface, or by non-covalent interactions such as hydrogen bonds, van der Waals forces, etc.
[0159] In other embodiments, the nucleic acid library can be double-stranded nucleic acid fragments, which are immobilized on the surface of a solid support by a ligation reaction with oligonucleotides immobilized on the surface of a solid support, and then a bridge amplification reaction is performed to prepare a sequencing library. Beneficial effects
[0160] The present invention can achieve the following beneficial effects:
[0161] The antioxidant composition of the present invention can be used as a nucleic acid protectant in nucleic acid detection, especially for double-end long-read sequencing, and can simultaneously improve the second-strand signal recovery value and Q30 value, and reduce the error rate.
[0162] The embodiments of the present invention will be described in detail below with reference to the accompanying drawings and examples. However, it will be understood by those skilled in the art that the following drawings and examples are intended only to illustrate the present invention and are not intended to limit the scope of the invention. Various objects and advantages of the present invention will become apparent to those skilled in the art based on the following detailed description of the accompanying drawings and preferred embodiments. BRIEF DESCRIPTION OF THE DRAWINGS
[0163] FIG1 is a Q30 (%) curve of Example 1 in which glycyrrhizic acid and monosodium adenosine 5'-monophosphate were added to the notoginsenoside R1 scanning reagent and sequencing was performed.
[0164] FIG2 is a Q30 (%) curve of Example 2 in which glycyrrhizic acid and carnosine are added to the notoginsenoside R1 scanning reagent and sequencing is performed. DETAILED DESCRIPTION
[0165] The embodiments of the present invention will be described in detail below with reference to the examples, but it will be understood by those skilled in the art that the following examples are merely illustrative of the present invention and should not be construed as limiting the scope of the invention. Where specific conditions are not specified in the examples, the methods were performed according to conventional conditions or the conditions recommended by the manufacturer. Where the manufacturers of the reagents or instruments are not specified, they are all conventional products that can be obtained commercially.
[0166] The sequencing slide is loaded with single-stranded DNA nanoballs (DNBs) containing E. coli genomic DNA. In Examples 1 and 2 below, imaging tests were performed using MGI sequencing slides (MGISEQ-2000RS sequencing slides), with a spacing of 900 nm and a binding area of approximately 200 nm; the kit is from DNBSEQ-G400HM. TM High-throughput sequencing kit (FCL PE100); library from standard library reagent V3.0 (26 ng / tube, E320, Barcode 97-104).
[0167] Example 1 Detection and evaluation of the effects of notoginsenoside R1+glycyrrhizic acid+5'-adenosine monophosphate monosodium on the second-strand Q30 decrease value, error rate and signal recovery value.
[0168] 1. Experimental materials (main reagents and consumables)
[0169] Table 1 Reagents and consumables information
[0170]
[0171]
[0172] 2. Instruments
[0173] Table 2 Instrument information
[0174] Instrument Model Instrument Number Sequencer MGISEQ-2000RSR10040100210039 Gene Amplifier 6337180005432N00099 Qubit Instrument Qubit4.0180005432N00006 Analytical Balance MS204TS180005436N00082
[0175] 3. Experimental Samples
[0176] Table 3 Sample information
[0177]
[0178] 4. Experimental Design
[0179] Different concentrations of 5'-adenosine monophosphate (ADP) and glycyrrhizic acid were added to the Notoginsenoside R1 scanning reagent (containing 1M Tris buffer, 1.67mM Notoginsenoside R1, 8mM Trolox, 10mM EDTA, and 20mM DTT). A control scanning reagent without ADP and glycyrrhizic acid was also prepared. PE150 sequencing was performed on the same MGISEQ-2000RS sequencer. Sequencing quality was compared after the sequencing was completed using different scanning reagents. Data from the different scanning reagents were compared, particularly regarding second-strand Q30 (%), second-strand Q30 decrease (%), error rate (%), and signal rebound.
[0180] 5. Evaluation indicators and standards
[0181] Table 4 Evaluation criteria
[0182] Evaluation index qualification standard Di-chain Q30 (%) The higher the better or the value is equivalent Di-chain Q30 decrease value (%) The lower the better or the value is equivalent
[0183] The lower the error rate (%), the better or the value is equivalent. The higher the signal recovery value, the better or the value is equivalent.
[0184] Q30 refers to the proportion of bases in the basecall results with an estimated error rate below 0.001 (accuracy greater than 99.9%); the error rate refers to the average number of mismatches at each site in the mapped reads; and the signal recovery value, a metric specific to the PE sequencing portion, reflects the recovery of the second-strand signal. These three indicators are generally selected as evaluation criteria for the gain effect of scanning reagents, and the three indicators of the experimental and control groups are compared. For example, if the Q30 indicator in the test report is higher in the experimental group than in the control group, it indicates that the added compound combination has a gain effect on sequencing. The higher the Q30 of the experimental group compared to the test group, the stronger the gain effect.
[0185] 6. Experimental Procedure
[0186] a. Preparation of DNB
[0187] 1) Remove DNB Preparation Buffer, DNB Polymerase Mix I, TE Buffer, and DNB Stop Buffer and place on ice for approximately 0.5 h. Once thawed, vortex and mix for 5 seconds. Briefly centrifuge and place on ice until ready for use.
[0188] 2) Using a 0.2 mL eight-tube strip or PCR tube, prepare the reaction mixture on ice as follows:
[0189] Component volume (μL) Library ssDNA 3 TE buffer 17 DNB preparation buffer 20 Total volume 40
[0190] 3) Vortex the reaction mixture and centrifuge for 5 seconds. Place the mixture in a PCR instrument for primer hybridization. The reaction conditions are shown in the table below:
[0191] Temperature Time Hot cover (105℃) On 95℃ 1min 65℃ 1min 40℃ 1min 4℃ Hold
[0192] 4) Remove the DNB polymerase mixture II (LC) and place it on ice. Centrifuge briefly for 5 seconds and place it on ice until ready to use.
[0193] 5) When the PCR instrument reaches 4°C, remove the PCR tube and centrifuge for 5 seconds. Then, add the following components on ice:
[0194] Components 100 μL System Addition Volume (μL) DNB Polymerase Mix I 40 DNB Polymerase Mix II (LC) 4
[0195] 6) The reaction mixture was vortexed and centrifuged for 5 seconds. The reaction mixture was immediately placed in a PCR instrument. The reaction conditions were as follows:
[0196] Temperature Time Hot Cover (35℃) On 30℃ 25min 4℃ Hold
[0197] 7) When the PCR instrument reaches 4°C, remove the PCR tube, add 20 μL of stop buffer, and mix slowly 5-8 times with a wide-mouth pipette tip.
[0198] 8) After DNB preparation, take 2 μL DNB and use ssDNA Assay Kit and The concentration was detected by Fluorometer instrument and the concentration was 15.3 ng / μL.
[0199] b. Prepare the slide and sequencing reagent tank
[0200] 1) Remove the slide from the -25°C to -15°C freezer and place it at room temperature for at least 60 minutes (no more than 24 hours).
[0201] 2) Remove DNB Loading Buffer II and place on ice for approximately 0.5 h to thaw. Vortex mix for 5 seconds, centrifuge briefly, and place on ice until ready for use.
[0202] 3) Take out a new 1.5 mL centrifuge tube and prepare the DNB loading system as shown in the table below:
[0203] Component FCL Addition volume (μL) DNB loading buffer II 33DNB99 Total volume 132
[0204] 4) Mix the DNB loading system slowly 5-8 times using a wide-mouth pipette tip.
[0205] 5) Take out the MGIDL-200H portable injector and install the sealing gasket into the sealing gasket groove. Install the chips into the injector.
[0206] 6) Use a flared pipette tip to load 27 μL of DNB onto L01-L04 respectively and let it stand at room temperature for more than half an hour.
[0207] 7) Prepare a PE150 sequencing reagent tank and take out the required HotMPS dNTP Mix and HotMPS dNTP Mix II 1 hour in advance. Thaw them at room temperature and set aside.
[0208] 8) Before use, remove Adv Seqenzyme II and place on ice.
[0209] 9) Add samples according to the table below:
[0210] Reagents: Well 1, Well 2, Well 15: HotMP SdNTP Mix 1500μL / HotMPS dNTP Mix II 1500μL / Adv Seqenzyme II 1000μL / MDA Reagent + MDA Enzyme / / 3875μL + 125μL
[0211] 10) Mix the reagents and set aside.
[0212] c. Sequencing
[0213] Place the reagent tank into the instrument, edit the script, and start PE150 sequencing.
[0214] Table 5 Experimental design
[0215] Experimental group number Condition 1 Notoginsenoside R1 scanning reagent 2 Notoginsenoside R1 scanning reagent + 0.5 mM glycyrrhizic acid + 7.5 mM 5'-adenosine monophosphate monosodium 3 Notoginsenoside R1 scanning reagent + 1.5 mM glycyrrhizic acid + 7.5 mM 5'-adenosine monophosphate monosodium 4 Notoginsenoside R1 scanning reagent + 2.5 mM glycyrrhizic acid + 7.5 mM 5'-adenosine monophosphate monosodium
[0216] PE150 sequencing was performed using a DNB template and fluorescently labeled nucleotides with reversible terminators. The reversible terminator nucleotides have a cleavable structure located at the base-linked fluorescent group and at the 3'-OH position of the ribose sugar. During each cycle, DNA polymerase was used to incorporate the nucleotides, and a scanning reagent was pumped in before imaging. Images were taken using an MGISEQ-2000RS imaging instrument. The fluorescent dyes were illuminated at excitation wavelengths of approximately 532 nm and 660 nm, with exposure times of 40 milliseconds for cycles 1-100, 40 milliseconds for cycles 100-200, and 50 milliseconds for cycles 200-300. After each cycle, the fluorescent group and protecting group were removed with 10 mM THPP.
[0217] Figure 1 shows the Q30 (%) curves of each sequencing group. As shown in the figure, compared with the notoginsenoside R1 scanning reagent, the Q30 (%) of the second chain added with different concentrations of glycyrrhizic acid and 5'-monophosphate monosodium decreased in the range of 7-11.3, all below 13.
[0218] Table 6 shows the test results for each evaluation indicator. PE150 sequencing results were obtained using the notoginsenoside R1 scanning reagent and its base reagents with the addition of glycyrrhizic acid and 5'-adenosine monophosphate. Compared to the notoginsenoside R1 scanning reagent, the second-strand Q30 (%) values for the reagents supplemented with different concentrations of glycyrrhizic acid and 5'-adenosine monophosphate were all around 94, higher than 92; the second-strand Q30 decrease values (%) ranged from 7 to 11.3, all lower than 13; the second-strand error rate (%) ranged from 0.18 to 0.35, all lower than 0.58; and the signal recovery values ranged from 2.14 to 2.32, all higher than 2.
[0219] Table 6 Effects of adding glycyrrhizic acid and monosodium adenosine 5'-monophosphate to the notoginsenoside R1 scanning reagent on dichalcone Q30 (%), dichalcone Q30 decrease value (%), error rate (%) and signal recovery value.
[0220]
[0221]
[0222] These results indicate that including different concentrations of glycyrrhizic acid and monosodium adenosine 5'-monophosphate in the notoginsenoside R1 scanning reagent can reduce the degradation of sequencing quality caused by the effects of photodamage on the DNA template, the extending chain, or both.
[0223] Example 2 Detection and evaluation of the effects of adding glycyrrhizic acid and carnosine to the notoginsenoside R1 scanning reagent on di-chain Q30 (%), di-chain Q30 decrease value (%), error rate (%) and signal recovery value.
[0224] The experimental plan was the same as Example 1, except that the scanning reagent of the test group was replaced.
[0225] Experimental group number Condition 1 Notoginsenoside R1 scanning reagent 2 Notoginsenoside R1 scanning reagent + 0.5mM glycyrrhizic acid + 7.5mM carnosine 3 Notoginsenoside R1 scanning reagent + 1mM glycyrrhizic acid + 7.5mM carnosine
[0226] Figure 2 shows the Q30 (%) curves of each sequencing group. As shown in the figure, compared with the notoginsenoside R1 scanning reagent, the notoginsenoside R1 scanning reagent with different concentrations of glycyrrhizic acid and carnosine dichain can reduce the Q30 value (%) by about 9-12, which is lower than 13.
[0227] Table 7 shows the sequencing results of PE150 sequencing using the notoginsenoside R1 scanning reagent and its base with glycyrrhizic acid and carnosine. Compared to the notoginsenoside R1 scanning reagent, the second-strand Q30 (%) of the samples supplemented with glycyrrhizic acid and carnosine at varying concentrations was approximately 93, higher than 92; the second-strand Q30 decrease (%) was approximately 9-12, lower than 13; the second-strand error rate (%) was approximately 0.35, lower than 0.58; and the signal recovery value was 2.17-2.44, higher than 2.
[0228] Table 7 Effects of adding glycyrrhizic acid and carnosine to the notoginsenoside R1 scanning reagent on di-chain Q30 (%), di-chain Q30 decrease value (%), error rate (%) and signal recovery value.
[0229]
[0230] These results indicate that including different concentrations of glycyrrhizic acid and carnosine in the notoginsenoside R1 scanning reagent can reduce the degradation of sequencing quality caused by the effects of photodamage on the DNA template, the extending chain, or both.
[0231] The above embodiments are only used to illustrate the technical solutions of the present invention and are not intended to limit the scope of the present invention. Any modification or equivalent replacement of the technical solutions of the present invention without departing from the purpose and scope of the technical solutions of the present invention should be included in the scope of protection of the present invention.
Claims
1. A composition comprising: (1) Saponin compounds, selected from one or more of notoginsenoside R1, ginsenoside Rg1, ginsenoside Rd, ginsenoside Rb2, ginsenoside Rb3, ginsenoside Rc, ginsenoside Rf, and ginsenoside Re; (2) glycyrrhizic acid, a salt of glycyrrhizic acid, or a hydrate of a salt of glycyrrhizic acid; and (3) adenosine 5'-monophosphate or its salts, or carnosine; Optionally, the composition may also contain other antioxidants.
2. The composition according to claim 1, wherein The saponin compound is notoginsenoside R1, and / or the salt of 5'-adenosine monophosphate is the sodium salt of 5'-adenosine monophosphate (eg monosodium 5'-adenosine monophosphate).
3. The composition according to claim 1 or 2, wherein the other antioxidant is selected from dithiothreitol (DTT) and Trolox (water-soluble vitamin E).
4. A reagent comprising the composition according to any one of claims 1 to 3 and a buffer solution (e.g., a Tris buffer solution); Preferably, the pH of the reagent is 6.0 to 9.0; Preferably, in the reagent, the concentration of the glycyrrhizic acid, the salt of glycyrrhizic acid or the hydrate of the salt of glycyrrhizic acid is 0.1 to 10 mM; Preferably, in the reagent, the concentration of the adenosine 5'-monophosphate or its salt or carnosine is 0.1 to 200 mM; Preferably, in the reagent, the concentration of the other antioxidant is 0.1 to 50 mM; Preferably, the reagent is a scanning reagent.
5. Use of the composition according to any one of claims 1 to 3 or the reagent according to claim 4 as a nucleic acid protective agent in nucleic acid detection; Preferably, the nucleic acid detection involves a light reaction or a non-light reaction (such as a bioluminescent reaction); Preferably, the nucleic acid detection involves a sequencing reaction; Preferably, the nucleic acid detection is nucleic acid sequence determination, such as high-throughput sequencing, such as SBS sequencing, ligation sequencing, hybridization sequencing, nanopore sequencing, or cPAL sequencing; Preferably, the nucleic acid detection is quantitative PCR.
6. A kit comprising the composition of any one of claims 1 to 3 or the reagent of claim 4; Preferably, the kit comprises one or more other reagents required for nucleic acid detection, such as primers, polymerase, buffer solution, washing solution, or any combination thereof.
7. A method for detecting a nucleic acid sequence, comprising: One or more labeled modified nucleotides are incorporated into a nucleic acid chain complementary to a nucleic acid template chain, and the type of the one or more incorporated nucleotides is determined by detecting the label, wherein the step of determining the type of incorporated nucleotides is performed in a buffer solution comprising the composition of any one of claims 1 to 3.
8. The method of claim 7, wherein the label is a label that can generate a fluorescent signal; Preferably, the fluorescent signal is generated by a light reaction or a bioluminescent reaction; Preferably, the labeled modified nucleotide is: (1) a fluorescently labeled nucleotide (eg, dNTP); or (2) a nucleotide with a tag (eg, dNTP), wherein the tag can specifically bind to luciferase.
9. The method according to claim 8, wherein The step of determining the type of incorporated nucleotide comprises: in the presence of the composition or reagent, applying conditions that allow the label to generate a fluorescent signal and detecting the fluorescent signal of the buffer and determining the identity of the incorporated nucleotide; Optionally, the method further comprises: removing from the incorporated nucleotide a portion directly or indirectly linked thereto that can generate a fluorescent signal; and / or, washing to remove unincorporated nucleotides; Preferably, the method comprises multiple incorporation and determining the identity of the base present in each incorporated nucleotide to determine the sequence of the target nucleic acid molecule.
10. The method according to any one of claims 7 to 9, wherein the buffer solution is a Tris buffer solution; Preferably, the pH of the buffer solution is 6.0 to 9.0; Preferably, in the buffer solution, the concentration of the glycyrrhizic acid, the salt of glycyrrhizic acid or the hydrate of the salt of glycyrrhizic acid is 0.1 to 10 mM; Preferably, in the buffer solution, the concentration of the adenosine 5'-monophosphate or its salt or carnosine is 0.1 to 200 mM; Preferably, in the buffer solution, the concentration of the other antioxidant is 0.1 to 50 mM; Preferably, the buffer solution is a scanning reagent.
